Profile data is unavailable for this security.
About the company
Shanghai MicuRx Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development (R&D) and commercialization of innovative drugs. The Company's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The Company also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The Company operates its businesses primarily in the domestic market.
- Revenue in CNY (TTM)136.70m
- Net income in CNY-342.96m
- Incorporated2012
- Employees188.00
- LocationShanghai MicuRx Pharmaceutical Co LtdBuilding 2, 101, 1-4F, Building 1, No. 5SHANGHAI 201210ChinaCHN
- Phone+86 2 150900550
- Fax+86 2 161101898
- Websitehttp://www.micurxchina.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Shen Lian Biomedical Corp | 292.81m | -30.34m | 3.95bn | 391.00 | -- | 2.80 | -- | 13.48 | -0.0739 | -0.0739 | 0.713 | 3.43 | 0.1864 | 1.42 | 0.9144 | 748,865.90 | -2.21 | 3.53 | -2.40 | 3.80 | 57.36 | 73.49 | -11.87 | 16.93 | 3.64 | -- | 0.0106 | 43.52 | 0.6394 | 3.63 | -241.95 | -- | -3.99 | -- |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 649.78m | 132.39m | 4.19bn | 1.12k | 31.66 | 1.81 | -- | 6.45 | 0.668 | 0.668 | 3.30 | 11.66 | 0.2093 | 0.6222 | 8.34 | 581,201.90 | 4.26 | 8.88 | 4.86 | 10.35 | 78.29 | 83.01 | 20.37 | 28.55 | 3.19 | -- | 0.1984 | 45.94 | -11.81 | 4.81 | -31.34 | 7.12 | 40.84 | 0.3458 |
| Shanghai MicuRx Pharmaceutical Co Ltd | 136.70m | -342.96m | 4.20bn | 188.00 | -- | 16.29 | -- | 30.72 | -0.5197 | -0.5197 | 0.2077 | 0.3929 | 0.161 | 0.4661 | 3.95 | 727,105.00 | -40.40 | -31.40 | -53.04 | -35.41 | 84.26 | 82.42 | -250.89 | -503.67 | 2.15 | -406.30 | 0.5862 | -- | 43.51 | -- | -4.65 | -- | 51.72 | -- |
Data as of Feb 11 2026. Currency figures normalised to Shanghai MicuRx Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 3.39m | 0.98% |
| Chang Xin Asset Management Co., Ltd.as of 30 Jun 2025 | 1.80m | 0.52% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 954.40k | 0.28% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 695.30k | 0.20% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 657.07k | 0.19% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2025 | 500.00k | 0.15% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 362.70k | 0.11% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 332.38k | 0.10% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 230.50k | 0.07% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 188.35k | 0.06% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
